NZ733854A - Pd-1 / pd-l1 inhibitors for the treatment of cancer - Google Patents

Pd-1 / pd-l1 inhibitors for the treatment of cancer

Info

Publication number
NZ733854A
NZ733854A NZ733854A NZ73385416A NZ733854A NZ 733854 A NZ733854 A NZ 733854A NZ 733854 A NZ733854 A NZ 733854A NZ 73385416 A NZ73385416 A NZ 73385416A NZ 733854 A NZ733854 A NZ 733854A
Authority
NZ
New Zealand
Prior art keywords
antibody
cancer
patients
treatment
avelumab
Prior art date
Application number
NZ733854A
Other languages
English (en)
Inventor
Jean-Marie Cuillerot
Anja Von Heydebreck
Guojun Yuan
Original Assignee
Merck Patent Gmbh
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Pfizer filed Critical Merck Patent Gmbh
Publication of NZ733854A publication Critical patent/NZ733854A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ733854A 2015-02-26 2016-02-23 Pd-1 / pd-l1 inhibitors for the treatment of cancer NZ733854A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562121025P 2015-02-26 2015-02-26
US201562133721P 2015-03-16 2015-03-16
US201562160291P 2015-05-12 2015-05-12
US201562215394P 2015-09-08 2015-09-08
US201562254424P 2015-11-12 2015-11-12
PCT/US2016/019120 WO2016137985A1 (en) 2015-02-26 2016-02-23 Pd-1 / pd-l1 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
NZ733854A true NZ733854A (en) 2022-07-01

Family

ID=55588542

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ733854A NZ733854A (en) 2015-02-26 2016-02-23 Pd-1 / pd-l1 inhibitors for the treatment of cancer

Country Status (15)

Country Link
US (2) US10800846B2 (cg-RX-API-DMAC7.html)
EP (2) EP4279087A3 (cg-RX-API-DMAC7.html)
JP (3) JP6885869B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170132171A (cg-RX-API-DMAC7.html)
CN (2) CN112263677A (cg-RX-API-DMAC7.html)
AU (3) AU2016222928B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017018234A2 (cg-RX-API-DMAC7.html)
CA (1) CA2977767C (cg-RX-API-DMAC7.html)
IL (2) IL278423B2 (cg-RX-API-DMAC7.html)
MX (2) MX393976B (cg-RX-API-DMAC7.html)
NZ (1) NZ733854A (cg-RX-API-DMAC7.html)
RU (1) RU2714233C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201706918YA (cg-RX-API-DMAC7.html)
TW (2) TWI748942B (cg-RX-API-DMAC7.html)
WO (1) WO2016137985A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX349096B (es) * 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding anti-pdl1 antibodie and methods of producing same
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
US11008391B2 (en) 2015-08-11 2021-05-18 WuXi Biologics Ireland Limited Anti-PD-1 antibodies
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
BR112018010211A2 (pt) 2015-12-07 2019-02-05 Merck Patent Gmbh formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
WO2017202744A1 (en) * 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
EP3471722B1 (en) 2016-06-17 2023-10-25 The Trustees of the University of Pennsylvania Compounds, compositions and methods for prevention and/or treatment of cancer
EA201990672A1 (ru) * 2016-09-14 2019-08-30 Бэйцзин Ханми Фарм. Ко., Лтд. Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
EP4541423A3 (en) * 2016-10-06 2025-06-25 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
AU2017373945B2 (en) 2016-12-07 2025-01-23 Agenus Inc. Antibodies and methods of use thereof
EP3582805A4 (en) * 2017-02-16 2021-03-10 MedImmune, LLC ANTI-PD-L1 ANTIBODY TREATMENT FOR BLADDER CANCER
KR20190125363A (ko) 2017-03-06 2019-11-06 메르크 파텐트 게엠베하 수성 항-pd-l1 항체 제제
EP3372615A1 (en) 2017-03-06 2018-09-12 Merck Patent GmbH Composition comprising avelumab
KR102644408B1 (ko) * 2017-03-30 2024-03-07 메르크 파텐트 게엠베하 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
MX2020003361A (es) * 2017-10-13 2020-07-29 Merck Patent Gmbh Combinacion de un inhibidor parp y un antagonista de union al eje pd-1.
WO2019118855A1 (en) * 2017-12-14 2019-06-20 The Trustees Of The University Of Pennsylvania Compounds and compositions for prevention and/or treatment of cancer
CN111741978A (zh) 2018-02-21 2020-10-02 戊瑞治疗有限公司 B7-h4抗体制剂
JP7430924B2 (ja) * 2018-03-22 2024-02-14 ケイレス アーゲー 拮抗的抗原結合タンパク質
SG11202012426WA (en) * 2018-06-13 2021-01-28 Merck Patent Gmbh Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
CA3114024A1 (en) * 2018-09-26 2020-04-02 Merck Patent Gmbh Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
EP3867274A1 (en) * 2018-10-15 2021-08-25 Five Prime Therapeutics, Inc. Combination therapy for cancer
SG11202105078XA (en) * 2018-11-14 2021-06-29 Bayer Ag Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
US11851490B2 (en) 2019-08-15 2023-12-26 Northwestern University Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
US20210169979A1 (en) * 2019-12-05 2021-06-10 The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges System and method for sonosensitized cancer immunotherapy with nanoparticles
CN115151258A (zh) * 2020-01-02 2022-10-04 默沙东有限责任公司 使用pd-1拮抗剂、ilt4拮抗剂和乐伐替尼或盐的组合癌症治疗
AU2020466790B2 (en) * 2020-09-04 2025-07-10 Pharma Mar, S.A. Combination of lurbinectedin and immune checkpoint inhibitor
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
TW202404634A (zh) * 2022-04-05 2024-02-01 美商安進公司 胃癌的治療
WO2024137442A1 (en) 2022-12-21 2024-06-27 Gilead Sciences, Inc. Combination therapy for treating cancer

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000475A (en) 1908-12-31 1911-08-15 Rodney Robert Woodson Coal-mining pick.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
JPH07263576A (ja) 1994-03-25 1995-10-13 Hitachi Ltd 半導体集積回路装置およびその製造方法
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
AU2002258941A1 (en) * 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
JP2006522087A (ja) 2003-04-03 2006-09-28 ファイザー・インク Ａｇ０１３７３６を含んでなる剤形
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
BRPI0506726B8 (pt) 2004-01-07 2021-05-25 Chiron Corp anticorpo monoclonal específico para m-csf e usos deste
CN101094836A (zh) 2004-11-02 2007-12-26 辉瑞大药厂 制备吲唑化合物的方法
CN101052633A (zh) 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
KR20070058689A (ko) 2004-11-02 2007-06-08 화이자 인코포레이티드 인다졸 화합물의 제조 방법
CA2586177A1 (en) 2004-11-02 2006-05-11 Pfizer Inc. Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole
CA2586174A1 (en) 2004-11-02 2006-05-11 Brigitte Leigh Ewanicki Methods of preparing indazole compounds
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
CA2608952A1 (en) 2005-05-19 2006-11-23 Dwayne Thomas Friesen Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
CN104356236B (zh) * 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US20100055111A1 (en) 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
PT2134702T (pt) 2007-04-05 2017-07-31 Pfizer Prod Inc Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-(piridin-2-il)etenil]indazol adequadas para o tratamento de crescimento celular anormal em mamíferos
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
EP3239178A1 (en) 2007-12-14 2017-11-01 Bristol-Myers Squibb Company Binding molecules to the human ox40 receptor
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2350129B1 (en) * 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
MX343747B (es) 2009-11-24 2016-11-22 Medimmune Ltd Agentes de union diana contra b7-h1.
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
JP2013537966A (ja) 2010-08-31 2013-10-07 ジェネンテック， インコーポレイテッド バイオマーカー及び治療の方法
DK2614082T3 (en) 2010-09-09 2018-11-26 Pfizer 4-1BB BINDING MOLECULES
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
EP2748199B1 (en) 2011-08-23 2019-08-28 Board of Regents, The University of Texas System Anti-ox40 antibodies and methods of using the same
TW201531309A (zh) 2011-09-30 2015-08-16 Pfizer Ｎ-甲基-２-〔３-（（ｅ）-２-吡啶-２-基-乙烯基）-１ｈ-吲唑-６-基硫烷基〕苯甲醯胺之藥學組成物
SG11201401656PA (en) 2011-11-11 2014-10-30 Pfizer N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
EP2812022B1 (en) 2012-02-06 2019-06-26 Providence Health & Services - Oregon Method of monitoring cancer treatment using ox40 agonists
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
EA037351B8 (ru) * 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2904011B1 (en) * 2012-10-02 2017-08-23 Bristol-Myers Squibb Company Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
MY176706A (en) 2013-03-15 2020-08-19 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
EP2981281B1 (en) 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
MX2015014198A (es) 2013-04-12 2015-12-11 Morphosys Ag Anticuerpos cuyo objetivo es m-csf.
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
KR102661249B1 (ko) 2013-09-11 2024-04-25 메디뮨 리미티드 종양 치료용 항-ｂ7-ｈ1 항체
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
US10202454B2 (en) 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
EP3065772B1 (en) * 2013-11-05 2024-07-24 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
JP6568093B2 (ja) 2013-11-07 2019-08-28 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
WO2015088847A1 (en) 2013-12-11 2015-06-18 Glaxosmithkline Llc Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
SG10201808519VA (en) 2013-12-17 2018-10-30 Genentech Inc Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
AU2014364593A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
EP3527587A1 (en) 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
US9045545B1 (en) * 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
PT3102605T (pt) 2014-02-04 2019-02-12 Pfizer Combinação de um antagonista da mp-1 e um inibidor do rfcev para o tratamento do cancro
CA2942039A1 (en) 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
US20170088626A1 (en) 2014-03-05 2017-03-30 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
CA2949121A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
ES2916923T3 (es) * 2014-07-11 2022-07-06 Ventana Med Syst Inc Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
EP3171896A4 (en) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Targeting dna-pkcs and b7-h1 to treat cancer
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
EP3185866A1 (en) 2014-08-25 2017-07-05 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
IL251464B2 (en) * 2014-10-29 2023-03-01 Five Prime Therapeutics Inc Combination therapy for cancer
KR20170096112A (ko) 2014-11-17 2017-08-23 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
US20170326234A1 (en) 2014-12-02 2017-11-16 Celgene Corporation Combination therapies
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
US20180282415A1 (en) 2015-09-30 2018-10-04 Merck Patent Gmbh Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2017202744A1 (en) 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
EP4541423A3 (en) 2016-10-06 2025-06-25 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
KR102644408B1 (ko) * 2017-03-30 2024-03-07 메르크 파텐트 게엠베하 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용

Also Published As

Publication number Publication date
AU2021204217A1 (en) 2021-07-15
KR20170132171A (ko) 2017-12-01
CA2977767C (en) 2024-04-09
JP2018508512A (ja) 2018-03-29
AU2016222928B2 (en) 2021-05-13
TWI748942B (zh) 2021-12-11
IL278423B1 (en) 2023-12-01
TW201639597A (zh) 2016-11-16
US10800846B2 (en) 2020-10-13
EP4279087A3 (en) 2024-01-31
MX2022001757A (es) 2022-03-11
AU2016222928A1 (en) 2017-10-12
RU2017133273A3 (cg-RX-API-DMAC7.html) 2019-07-24
MX2017010773A (es) 2018-03-15
IL254131A0 (en) 2017-10-31
CN107405401B (zh) 2022-02-01
JP6885869B2 (ja) 2021-06-16
CA2977767A1 (en) 2016-09-01
RU2714233C2 (ru) 2020-02-13
CN107405401A (zh) 2017-11-28
US20180244781A1 (en) 2018-08-30
IL278423B2 (en) 2024-04-01
IL254131B (en) 2021-02-28
JP2020114840A (ja) 2020-07-30
IL278423A (cg-RX-API-DMAC7.html) 2020-12-31
EP3262073A1 (en) 2018-01-03
JP7116113B2 (ja) 2022-08-09
TWI755791B (zh) 2022-02-21
CN112263677A (zh) 2021-01-26
JP2021178822A (ja) 2021-11-18
SG10201810615VA (en) 2019-01-30
BR112017018234A2 (pt) 2018-04-17
WO2016137985A1 (en) 2016-09-01
TW202110480A (zh) 2021-03-16
SG11201706918YA (en) 2017-09-28
EP4279087A2 (en) 2023-11-22
AU2021204211A1 (en) 2021-07-15
US20200362040A1 (en) 2020-11-19
RU2017133273A (ru) 2019-03-27
MX393976B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
US20200362040A1 (en) Pd-1/pd-l1 inhibitors for the treatment of cancer
US20230272083A1 (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
JP2019515916A (ja) グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法
US12227577B2 (en) Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer
US20190216923A1 (en) Methods and combination therapy to treat cancer
HK40040793A (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
WO2024208253A1 (en) Compositions and methods for treating solid tumors with anti-btla as combination therapy
RU2742312C1 (ru) Ингибиторы pd-1 / pd-l1 для лечения рака
HK1242210A1 (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 FEB 2024 BY CPA GLOBAL

Effective date: 20230112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 FEB 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240111

LAPS Patent lapsed